<DOC>
	<DOCNO>NCT00126009</DOCNO>
	<brief_summary>The primary objective : - To compare efficacy association valproate-amisulpride ( 400 800 mg/day ) association valproate-haloperidol ( 5 15 mg/day ) bipolar I patient suffer manic episode accord DSM IV TR ( American Psychiatric Association [ APA ] 2000 ) treat 3-month period . The secondary objective : - To evaluate clinical biological safety association valproate-amisulpride association valproate-haloperidol ; - To assess patient status 3 week 3 month inclusion ; - To assess patient satisfaction 3 month .</brief_summary>
	<brief_title>SOLMANIA - Comparison Valproate-Amisulpride Valproate-Haloperidol Bipolar I Patients</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>PreInclusion Criteria D3 : Inpatients From 18 65 year old Able comply protocol Having give write informed consent ( legal representative person trust ) Current diagnosis bipolar I disorder accord DSM IV TR ( APA 2000 ) Having least one manic episode past Currently suffer manic episode accord DSM IV TR ( APA 2000 ) A minimum total score 20 Young Mania Rating Scale ( YMRS ) D3 Inclusion Criteria D0 : Having complete least one day one threeday washout period A minimum total score 20 Young Mania Rating Scale D0 A score &gt; = 3 2 follow YMRS item : elevate mood ; increase motor activity energy ; sleep ; content ( grandiosity ) . A score &gt; = 5 Clinical Global Impression Severity Scale severity mania item D0 Using effective contraception method ( woman childbearing age ) Exclusion Criteria D3 : Having participate clinical trial within three previous month Pregnant breastfeeding . Female patient therefore use reliable contraceptive method ( oral parenteral contraception , intrauterine device surgical sterilisation ) Uncontrolled gastrointestinal , renal , hepatic , endocrine , cardiovascular , pulmonary , immunological hematological disease Central nervous system ( CNS ) neoplasm ; demyelinate disease ; degenerative neurological disorder ; active CNS infection ; progressive disorder may confound interpretation study result Prolactindependant tumor Past current pancreatitis Acute hepatitis , chronic hepatitis , family history severe hepatitis , especially drug relate , hepatic porphyry Current recent ( within 3 month ) DSM IV diagnosis substance dependence ( exception nicotine caffeine dependence ) ; substance abuse stimulant include , limited , cocaine , crack , amphetamine , pseudoephedrine , cold medication phenylephrine , stimulant . Alcohol marijuana abuse prior study entry would acceptable related current manic episode , base investigator 's judgement Parkinson 's disease Phaeochromocytoma History epilepsy History allergy hypersensitivity haloperidol benzamides valproate Treated fluoxetin within past 4 week Treated injectable longacting neuroleptic , patient , interval 2 injection period elapse preinclusion ( D3 ) Treated mood stabiliser ( valproate ) effective dose less 7 day precede D3 modification justify Bradycardia &lt; 55 beat per minute ( bpm ) Known hypokaliaemia Congenital prolongation QT interval Treated following medication : Class Ia antiarrhythmic agent quinidine , disopyramide/Class III antiarrhythmic agent amiodarone , sotalol ; Drugs like : beperidil , cisapride , sultopride , thioridazine , intravenous ( IV ) erythromycin , IV vincamine , halofantrine , pentamidine , sparfloxacin . Exclusion Criteria D0 : Potentially significant alteration laboratory test D0 : ASAT ALAT &gt; 2 upper limit normal ( ULN ) . If ASAT ALAT value range 1.5 ULN 2 ULN , patient randomize new test perform 7 day randomization ; Alkaline phosphatase level bilirubin level within normal reference range . QTc prolongation D0 ; QTc Bazett &gt; 450ms male patient QTc &gt; 470ms female patient electrocardiogram ( ECG ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>